DK3692015T3 - Hidtil ukendte glutaminantagonister og anvendelser deraf - Google Patents

Hidtil ukendte glutaminantagonister og anvendelser deraf Download PDF

Info

Publication number
DK3692015T3
DK3692015T3 DK18864999.0T DK18864999T DK3692015T3 DK 3692015 T3 DK3692015 T3 DK 3692015T3 DK 18864999 T DK18864999 T DK 18864999T DK 3692015 T3 DK3692015 T3 DK 3692015T3
Authority
DK
Denmark
Prior art keywords
previously unknown
glutamine antagonists
antagonists
glutamine
unknown
Prior art date
Application number
DK18864999.0T
Other languages
English (en)
Inventor
Barbara Slusher
Pavel Majer
Lukas Tenora
Katerina Novotna
Jesse Alt
Rana Rais
Original Assignee
Univ Johns Hopkins
Ustav Organicke Chemie A Biochemie Av Cr V V I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Ustav Organicke Chemie A Biochemie Av Cr V V I filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3692015T3 publication Critical patent/DK3692015T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C245/18Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72Hydrazones
    • C07C251/74Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/32Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18864999.0T 2017-10-06 2018-10-05 Hidtil ukendte glutaminantagonister og anvendelser deraf DK3692015T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569118P 2017-10-06 2017-10-06
US201862728214P 2018-09-07 2018-09-07
PCT/US2018/054581 WO2019071110A1 (en) 2017-10-06 2018-10-05 NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK3692015T3 true DK3692015T3 (da) 2022-11-21

Family

ID=65994832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18864999.0T DK3692015T3 (da) 2017-10-06 2018-10-05 Hidtil ukendte glutaminantagonister og anvendelser deraf

Country Status (7)

Country Link
US (1) US12195419B2 (da)
EP (1) EP3692015B1 (da)
JP (1) JP7358342B2 (da)
CN (1) CN111566083A (da)
DK (1) DK3692015T3 (da)
ES (1) ES2930258T3 (da)
WO (1) WO2019071110A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520118A (zh) 2017-02-01 2019-11-29 约翰斯霍普金斯大学 谷氨酰胺类似物的前药
US20210177841A1 (en) * 2017-11-03 2021-06-17 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors
BR112021014112A2 (pt) * 2019-01-18 2021-10-13 Dracen Pharmaceuticals, Inc. Usos de composto pró-fármaco de don e inibidor de ponto de controle imunológico para tratar câncer, bem como composto e composição farmacêutica compreendendo o mesmo
JP2022519530A (ja) * 2019-02-11 2022-03-24 ドラセン ファーマシューティカルズ インコーポレイテッド L-ピログルタミン酸からdonプロドラッグを調製する方法
EP3924330A4 (en) 2019-02-11 2022-11-09 Dracen Pharmaceuticals, Inc. PROCESS FOR THE PREPARATION OF A DON-PRODRUGE FROM L-GLUTAMIC ACID
CA3133735A1 (en) * 2019-03-18 2020-09-24 Alteron Therapeutics, Inc. Modulators of tdp-43
WO2021239049A1 (en) * 2020-05-27 2021-12-02 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
WO2022022612A1 (en) * 2020-07-29 2022-02-03 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
CN116601140A (zh) 2020-10-02 2023-08-15 羿尊生物医药股份有限公司 用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途
AU2021361970A1 (en) * 2020-10-15 2023-06-15 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
WO2022078462A1 (en) * 2020-10-15 2022-04-21 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
WO2022232565A1 (en) * 2021-04-29 2022-11-03 The Johns Hopkins University Prodrugs of 6-diazo-5-oxo-l-norleucine
JP2025078888A (ja) * 2022-01-28 2025-05-21 国立大学法人富山大学 グルタミナーゼ阻害剤
TW202404938A (zh) * 2022-04-21 2024-02-01 大陸商北京加科思新藥研發有限公司 麩醯胺酸拮抗劑的多晶型及其用途
CN120265609A (zh) * 2022-11-02 2025-07-04 约翰霍普金斯大学 具有优先肿瘤递送的阿佐霉素前药

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
US20060276438A1 (en) * 2004-10-04 2006-12-07 Natarajan Sethuraman Prevention and treatment of influenza with glutamine antagonist agents
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2009029729A1 (en) 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
DK3328827T3 (da) * 2015-07-31 2023-10-02 Univ Johns Hopkins Prodrugs af glutaminanaloger
WO2017023791A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Glutamine antagonists for the treatment of cognitive deficits
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
CN110520118A (zh) 2017-02-01 2019-11-29 约翰斯霍普金斯大学 谷氨酰胺类似物的前药

Also Published As

Publication number Publication date
ES2930258T3 (es) 2022-12-09
EP3692015A1 (en) 2020-08-12
JP7358342B2 (ja) 2023-10-10
US20230009398A1 (en) 2023-01-12
CN111566083A (zh) 2020-08-21
WO2019071110A1 (en) 2019-04-11
US12195419B2 (en) 2025-01-14
EP3692015B1 (en) 2022-08-24
EP3692015A4 (en) 2021-06-30
JP2020536867A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
DK3596053T3 (da) Farnesoid-x-receptoragonister og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3609888T3 (da) Farnesoid x-receptor-agonister og anvendelser deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3497094T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
HRP20260151T1 (hr) Modificirani polipeptidi i njihova uporaba
DK3551221T3 (da) Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
IL254394A0 (en) Transposase polypeptides and uses thereof
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3264955T3 (da) Blandeanordning og fremgangsmåde
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf